Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Oak Ridge Institute for Science and Education Fellowship Program, Oak Ridge, Tennessee, USA.
J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):75-82. doi: 10.1093/jpids/piaa017.
Annual United States (US) estimates of influenza vaccine effectiveness (VE) in children typically measure protection against outpatient medically attended influenza illness, with limited data evaluating VE against influenza hospitalizations. We estimated VE for preventing laboratory-confirmed influenza hospitalization among US children.
We included children aged 6 months-17 years with acute respiratory illness enrolled in the New Vaccine Surveillance Network during the 2015-2016 influenza season. Documented influenza vaccination status was obtained from state immunization information systems, the electronic medical record, and/or provider records. Midturbinate nasal and throat swabs were tested for influenza using molecular assays. We estimated VE as 100% × (1 - odds ratio), comparing the odds of vaccination among subjects testing influenza positive with subjects testing negative, using multivariable logistic regression.
Of 1653 participants, 36 of 707 (5%) of those fully vaccinated, 18 of 226 (8%) of those partially vaccinated, and 85 of 720 (12%) of unvaccinated children tested positive for influenza. Of those vaccinated, almost 90% were documented to have received inactivated vaccine. The majority (81%) of influenza cases were in children ≤ 8 years of age. Of the 139 influenza-positive cases, 42% were A(H1N1)pdm09, 42% were B viruses, and 14% were A(H3N2). Overall, adjusted VE for fully vaccinated children was 56% (95% confidence interval [CI], 34%-71%) against any influenza-associated hospitalization, 68% (95% CI, 36%-84%) for A(H1N1)pdm09, and 44% (95% CI, -1% to 69%) for B viruses.
These findings demonstrate the importance of annual influenza vaccination in prevention of severe influenza disease and of reducing the number of children who remain unvaccinated or partially vaccinated against influenza.
美国(US)每年对流感疫苗有效性(VE)的估计通常是衡量门诊接受医疗治疗的流感疾病的保护作用,而针对流感住院的 VE 评估数据有限。我们评估了美国儿童预防实验室确诊的流感住院的 VE。
我们纳入了在 2015-2016 流感季节参与新疫苗监测网络的年龄在 6 个月至 17 岁的急性呼吸道疾病患儿。从州免疫信息系统、电子病历和/或提供者记录中获取已记录的流感疫苗接种情况。使用分子检测方法从中鼻甲鼻和咽拭子中检测流感。我们通过多变量逻辑回归比较了流感阳性患儿与流感阴性患儿的疫苗接种几率,估计 VE 为 100%×(1-比值比)。
在 1653 名参与者中,707 名完全接种疫苗的儿童中有 36 名(5%)、226 名部分接种疫苗的儿童中有 18 名(8%)和 720 名未接种疫苗的儿童中有 85 名(12%)检测出流感阳性。接种疫苗的儿童中,几乎 90%有记录表明接种了灭活疫苗。大多数(81%)流感病例发生在≤8 岁的儿童中。在 139 例流感阳性病例中,42%为 A(H1N1)pdm09、42%为 B 病毒,14%为 A(H3N2)。总体而言,完全接种疫苗的儿童对任何与流感相关的住院的调整 VE 为 56%(95%可信区间 [CI],34%-71%),对 A(H1N1)pdm09 为 68%(95% CI,36%-84%),对 B 病毒为 44%(95% CI,-1%至 69%)。
这些发现表明,每年接种流感疫苗对于预防严重流感疾病和减少未接种或部分接种流感疫苗的儿童数量非常重要。